See-Mode Technologies, a MedTech startup based in Singapore and Australia that seeks to empower clinicians to better predict stroke, has recently announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its debut product, Augmented Vascular Analysis (AVA), a world-first medical Artificial Intelligence (AI) software for automated analysis and reporting of vascular ultrasound scans.

AVA uses deep learning, text recognition, and signal processing technologies to assist clinicians in interpreting and reporting vascular ultrasound studies – typically a manual and error-prone process. With a single click and in less than a minute, AVA can analyze a full vascular ultrasound scan, minimizing the need for manual drawings. By significantly reducing the time taken to analyse images and generate reports, See-Mode's AVA augments the clinical workflow, resulting in greater overall productivity, accuracy and improved patient outcomes.

See-Mode is developing novel solutions to improve the analysis of routinely collected medical images such as ultrasound, CT or MRI scans. By applying AI and computational models on these medical images, clinicians are able to obtain stroke risk factors that may not be accessible in current clinical practice.

The startup has completed strong proofs-of-concept for both products with collaborators in Singapore and Australia, and multi-center clinical studies are now being conducted with partners across Europe and the United States.